Toxin-Induced Necroptosis Is a Major Mechanism of Staphylococcus aureus Lung Damage
0301 basic medicine
QH301-705.5
Inflammasomes
Bacterial Toxins
Blotting, Western
Toxinas bacterianas
610
Enzyme-Linked Immunosorbent Assay
Cell Line
Mice
Necrosis
03 medical and health sciences
Neumonía
Macrophages, Alveolar
Pneumonia, Staphylococcal
Animals
Humans
Biology (General)
RC581-607
Flow Cytometry
3. Good health
Mice, Inbred C57BL
Immunologic diseases. Allergy
Medicina y salud
Research Article
Signal Transduction
DOI:
10.1371/journal.ppat.1004820
Publication Date:
2015-04-16T13:53:44Z
AUTHORS (9)
ABSTRACT
Staphylococcus aureus USA300 strains cause a highly inflammatory necrotizing pneumonia. The virulence of this strain has been attributed to its expression of multiple toxins that have diverse targets including ADAM10, NLRP3 and CD11b. We demonstrate that induction of necroptosis through RIP1/RIP3/MLKL signaling is a major consequence of S. aureus toxin production. Cytotoxicity could be prevented by inhibiting either RIP1 or MLKL signaling and S. aureus mutants lacking agr, hla or Hla pore formation, lukAB or psms were deficient in inducing cell death in human and murine immune cells. Toxin-associated pore formation was essential, as cell death was blocked by exogenous K+ or dextran. MLKL inhibition also blocked caspase-1 and IL-1β production, suggesting a link to the inflammasome. Rip3(-/-) mice exhibited significantly improved staphylococcal clearance and retained an alveolar macrophage population with CD200R and CD206 markers in the setting of acute infection, suggesting increased susceptibility of these leukocytes to necroptosis. The importance of this anti-inflammatory signaling was indicated by the correlation between improved outcome and significantly decreased expression of KC, IL-6, TNF, IL-1α and IL-1β in infected mice. These findings indicate that toxin-induced necroptosis is a major cause of lung pathology in S. aureus pneumonia and suggest the possibility of targeting components of this signaling pathway as a therapeutic strategy.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (53)
CITATIONS (221)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....